During the works council held on June 4, 2013, Unda has announced its intention to reorganize its activities in order to ensure the development of homeopathy in Belgium.
It is planned to create two different companies in order to develop Unda medicines and Boiron medicines independently.
It is also planned to look for a buyer able to sustain the activity of Unda in Belgium and abroad.
This project, likely to have social effects on the two Belgian sites, could affect around 60 employees over 194.
Our next update:
July 12, 2013, after the close of the stock market, publication of 2013 half-year financial information.
Financial information manager: Philippe MONTANT
Contact for financial information: Véronique BOUSCAYROL
Investor relations: +33 (0) 18.104.22.168.43 - e-mail: email@example.com
ISIN Code: FR0000061129 (BOI) - Bloomberg : BOI FP - Reuters : BOIR.PA
The group's financial information is online at : www.boiron.com
Communiqués au titre de l'obligation d'information permanente :
- Autres communiqués Communiqué intégral et original au format PDF :
http://www.actusnews.com/documents_communiques/ACTUS-0-32314-cp-boiron_040613.pdf © Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
|BOIRON||Euronext Paris||76.38 (c)||-0.53%||1 789|